1. [O2–17–06]: SAFETY AND TOLERABILITY OF CRENEZUMAB IN MILD‐TO‐MODERATE AD PATIENTS TREATED WITH ESCALATING DOSES FOR UP TO 25 MONTHS. (1st July 2017) Authors: Asnaghi, Veronica; Lin, Helen; Hu, Nan; Smith, Jillian; Cho, William; Ostrowitzki, Susanne Journal: Alzheimer's & dementia Issue: Volume 13:Supplement 7S(2017)Part 12 Page Start: P602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer's Disease. (1st July 2016) Authors: Blaettler, Thomas; Smith, Janice; Smith, Jillian; Paul, Robert; Asnaghi, Veronica; Fuji, Reina; Quartino, Angelica; Honigberg, Lee; Rabbia, Michael A.; Yule, Susan; Ostrowitzki, Susanne; Fontoura, Paulo Journal: Alzheimer's & dementia Issue: Volume 12:Supplement 7S(2016)Part 12 Page Start: P609 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗